MSAM
CRSP icon

Moloney Securities Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Moloney Securities Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-13,161
Closed -$235K – 277
2017
Q3 		$235K Buy
+13,161
New +$239K 0.1% 222

Other funds holding CRSP

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GTP
Global Thematic Partners New York $120M AUM 25.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Moloney Securities Asset Management's CRSP Position: Q4 2017 in Review

Moloney Securities Asset Management sold out of CRISPR Therapeutics (CRSP) in Q4 2017, closing a stake of 13,161 shares — an estimated $235K sold.

Moloney Securities Asset Management first reported a position in CRSP in Q3 2017 and held it in 1 quarter. The position peaked at $235K in Q3 2017. 83 funds tracked by Wall St. Rank hold CRSP as of Q4 2017.

  • Moloney Securities Asset Management reported no remaining CRISPR Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Moloney Securities Asset Management sold 13,161 CRISPR Therapeutics shares in Q4 2017, an estimated $235K.
  • Moloney Securities Asset Management first reported a position in CRISPR Therapeutics in Q3 2017 and held it in 1 quarter.
  • Moloney Securities Asset Management's CRISPR Therapeutics position peaked at $235K in Q3 2017.
  • 83 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2017.

Based on Moloney Securities Asset Management's 13F filing for Q4 2017, filed 25 Jan 2018.